

Mangesh A Thorat

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1760151/mangesh-a-thorat-publications-by-citations.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

86 papers	10,198 citations	26 h-index	100 g-index
104 ext. papers	12,616 ext. citations	10 avg, IF	5.5 L-index

#	Paper	IF	Citations
86	The SCARE 2020 Guideline: Updating Consensus Surgical CAse REport (SCARE) Guidelines. <i>International Journal of Surgery</i> , 2020 , 84, 226-230	7.5	2300
85	The SCARE 2018 statement: Updating consensus Surgical CAse REport (SCARE) guidelines. <i>International Journal of Surgery</i> , 2018 , 60, 132-136	7.5	1971
84	The SCARE Statement: Consensus-based surgical case report guidelines. <i>International Journal of Surgery</i> , 2016 , 34, 180-186	7.5	1507
83	STROCCS 2019 Guideline: Strengthening the reporting of cohort studies in surgery. <i>International Journal of Surgery</i> , 2019 , 72, 156-165	7.5	855
82	The STROCCS statement: Strengthening the Reporting of Cohort Studies in Surgery. <i>International Journal of Surgery</i> , 2017 , 46, 198-202	7.5	662
81	The PROCESS 2018 statement: Updating Consensus Preferred Reporting Of CasE Series in Surgery (PROCESS) guidelines. <i>International Journal of Surgery</i> , 2018 , 60, 279-282	7.5	316
80	Preferred reporting of case series in surgery; the PROCESS guidelines. <i>International Journal of Surgery</i> , 2016 , 36, 319-323	7.5	311
79	Prevention and early detection of prostate cancer. <i>Lancet Oncology</i> , 2014 , 15, e484-92	21.7	277
78	The PROCESS 2020 Guideline: Updating Consensus Preferred Reporting Of CasESeries in Surgery (PROCESS) Guidelines. <i>International Journal of Surgery</i> , 2020 , 84, 231-235	7.5	254
77	Estimates of benefits and harms of prophylactic use of aspirin in the general population. <i>Annals of Oncology</i> , 2015 , 26, 47-57	10.3	241
76	FOXA1 expression in breast cancer--correlation with luminal subtype A and survival. <i>Clinical Cancer Research</i> , 2007 , 13, 4415-21	12.9	187
75	Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment. <i>Breast Cancer Research and Treatment</i> , 2010 , 123, 97-108	4.4	148
74	STROCCS 2021: Strengthening the reporting of cohort, cross-sectional and case-control studies in surgery. <i>International Journal of Surgery</i> , 2021 , 96, 106165	7.5	147
73	The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort. <i>Breast Cancer Research and Treatment</i> , 2011 , 126, 797-802	4.4	90
72	Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis. <i>Journal of Clinical Pathology</i> , 2008 , 61, 327-32	3.9	87
71	Role of aspirin in cancer prevention. <i>Current Oncology Reports</i> , 2013 , 15, 533-40	6.3	72
70	Absolute Quantitation of DNA Methylation of 28 Candidate Genes in Prostate Cancer Using Pyrosequencing. <i>Disease Markers</i> , 2011 , 30, 151-161	3.2	70

69	Prophylactic use of aspirin: systematic review of harms and approaches to mitigation in the general population. <i>European Journal of Epidemiology</i> , 2015 , 30, 5-18	12.1	47
68	Absolute quantitation of DNA methylation of 28 candidate genes in prostate cancer using pyrosequencing. <i>Disease Markers</i> , 2011 , 30, 151-61	3.2	47
67	Breast cancer prevention in high-risk women. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2020 , 65, 18-31	4.6	44
66	Expression of Forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low Oncotype DX 21-gene recurrence scores. <i>Modern Pathology</i> , 2010 , 23, 270-5	9.8	41
65	Subcellular localization of activated AKT in estrogen receptor- and progesterone receptor-expressing breast cancers: potential clinical implications. <i>American Journal of Pathology</i> , 2010 , 176, 2139-49	5.8	36
64	Impact of preventive therapy on the risk of breast cancer among women with benign breast disease. <i>Breast</i> , 2015 , 24 Suppl 2, S51-5	3.6	28
63	Association between DNA methylation of HSPB1 and death in low Gleason score prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2013 , 16, 35-40	6.2	27
62	STROCSS 2021: Strengthening the reporting of cohort, cross-sectional and case-control studies in surgery. <i>Annals of Medicine and Surgery</i> , 2021 , 72, 103026	2	27
61	Performance of the Xpert HPV assay in women attending for cervical screening. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2015 , 1, 32-37	4.6	26
60	Prostanoid receptor EP1 expression in breast cancer. <i>Modern Pathology</i> , 2008 , 21, 15-21	9.8	25
59	Prognosis of hormone-dependent breast cancers: implications of the presence of dysfunctional transcriptional networks activated by insulin via the immune transcription factor T-bet. <i>Cancer Research</i> , 2010 , 70, 685-96	10.1	22
58	STROCSS 2021: Strengthening the reporting of cohort, cross-sectional and case-control studies in surgery. <i>International Journal of Surgery Open</i> , 2021 , 100430	0.9	22
57	Loss of ER α and FOXA1 expression in a progression model of luminal type breast cancer: insights from PyMT transgenic mouse model. <i>Oncology Reports</i> , 2010 , 24, 1233-9	3.5	19
56	Role of glucocorticoids in breast cancer. <i>Current Pharmaceutical Design</i> , 2010 , 16, 3593-600	3.3	19
55	Barriers to preventive therapy for breast and other major cancers and strategies to improve uptake. <i>Ecancermedicalscience</i> , 2015 , 9, 595	2.7	17
54	DNA methylation gene-based models indicating independent poor outcome in prostate cancer. <i>BMC Cancer</i> , 2014 , 14, 655	4.8	15
53	Preventing invasive breast cancer using endocrine therapy. <i>Breast</i> , 2017 , 34 Suppl 1, S47-S54	3.6	13
52	Revision surgery for breast cancer: single-institution experience. <i>Cancer</i> , 2008 , 113, 2347-52	6.4	13

51	Beliefs About Medication and Uptake of Preventive Therapy in Women at Increased Risk of Breast Cancer: Results From a Multicenter Prospective Study. <i>Clinical Breast Cancer</i> , 2019 , 19, e116-e126	3	13
50	ITF2 is a target of CXCR4 in MDA-MB-231 breast cancer cells and is associated with reduced survival in estrogen receptor-negative breast cancer. <i>Cancer Biology and Therapy</i> , 2010 , 10, 600-14	4.6	12
49	Quantitative DNA methylation and recurrence of breast cancer: a study of 30 candidate genes. <i>Cancer Biomarkers</i> , 2012 , 11, 75-88	3.8	12
48	Differential subcellular expression of protein kinase C beta11 in breast cancer: correlation with breast cancer subtypes. <i>Breast Cancer Research and Treatment</i> , 2010 , 124, 327-35	4.4	12
47	Sentinel-node biopsy in breast cancer. <i>New England Journal of Medicine</i> , 2003 , 349, 1968-71; author reply 1968-71	59.2	11
46	Letrozole-induced necrotising leukocytoclastic small vessel vasculitis: First report of a case in the UK. <i>International Journal of Surgery Case Reports</i> , 2015 , 16, 77-80	0.8	10
45	Quantitative nuclear histomorphometric features are predictive of Oncotype DX risk categories in ductal carcinoma in situ: preliminary findings. <i>Breast Cancer Research</i> , 2019 , 21, 114	8.3	10
44	Differential gene expression profiling of esophageal adenocarcinoma. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2009 , 137, 829-34	1.5	10
43	Amplified in breast cancer 1 expression in breast cancer. <i>Histopathology</i> , 2008 , 53, 634-41	7.3	9
42	Uptake characteristics of FDG in multiple juvenile cellular fibroadenomata of the breast: FDG-PET and histopathologic correlation. <i>Clinical Nuclear Medicine</i> , 2007 , 32, 203-4	1.7	8
41	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. <i>JNCI Cancer Spectrum</i> , 2019 , 3, pkz050	4.6	6
40	13-gene signature to predict rapid development of brain metastases in patients with HER2-positive advanced breast cancer.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 505-505	2.2	6
39	FOXP3 expression and nodal metastasis of breast cancer. <i>Cellular Oncology (Dordrecht)</i> , 2013 , 36, 405-9	7.2	5
38	Five genetic variants associated with prostate cancer. <i>New England Journal of Medicine</i> , 2008 , 358, 2738; author reply 2741	59.2	5
37	Radiation therapy for ductal carcinoma in situ: is it really worth it?. <i>Journal of Clinical Oncology</i> , 2007 , 25, 461-2; author reply 462	2.2	5
36	Optimum cancer care--an unaffordable goal?. <i>Lancet Oncology, The</i> , 2004 , 5, 529-30	21.7	5
35	Gene expression analysis for prediction of early brain metastasis (BM) in HER2-positive (HER2+) breast cancer patients (pts). <i>Journal of Clinical Oncology</i> , 2008 , 26, 1019-1019	2.2	5
34	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. <i>JNCI Cancer Spectrum</i> , 2019 , 3, pkz049	4.6	4

33	COX-2 expression does not correlate with microvessel density in breast cancer. <i>Pathobiology</i> , 2009 , 76, 39-44	3.6	4
32	Tuning into the genetic orchestra using microarrays: limitations of DNA microarrays in clinical practice. <i>Nature Clinical Practice Oncology</i> , 2006 , 3, E1		4
31	Prognostic Value of ER and PgR Expression and the Impact of Multi-clonal Expression for Recurrence in Ductal Carcinoma : Results from the UK/ANZ DCIS Trial. <i>Clinical Cancer Research</i> , 2021 , 27, 2861-2867	12.9	4
30	Autoantibodies in prostate cancer. <i>New England Journal of Medicine</i> , 2005 , 353, 2815-7; author reply 2815-7	59.2	3
29	Prognostic and Predictive Value of HER2 Expression in Ductal Carcinoma : Results from the UK/ANZ DCIS Randomized Trial. <i>Clinical Cancer Research</i> , 2021 ,	12.9	3
28	Should we undertake an MRI breast screening trial?. <i>Lancet, The</i> , 2007 , 370, 1902; author reply 1903-4	40	2
27	Are there distinct lymphatic flow patterns in the Breast?. <i>Medical Hypotheses</i> , 2006 , 66, 1040-1	3.8	2
26	Abstract P3-07-02: Prognostic and predictive relevance of HER2 status in ductal carcinoma in situ: Results from the UK/ANZ DCIS trial 2016 ,		2
25	Delivering brief physical activity interventions in primary care: a systematic review. <i>British Journal of General Practice</i> , 2021 ,	1.6	2
24	Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review. <i>The Cochrane Library</i> , 2021 , 10, CD013091	5.2	2
23	VEGFA amplification/deletion in human breast tumors.. <i>Journal of Clinical Oncology</i> , 2010 , 28, e21017-e21017	21.7	2
22	Individualised benefit-harm balance of aspirin as primary prevention measure - a good proof-of-concept, but could have been better <i>BMC Medicine</i> , 2016 , 14, 101	11.4	2
21	Assessing opportunities for coordinated R&D in early cancer detection and management in Europe. <i>International Journal of Cancer</i> , 2017 , 140, 1700-1701	7.5	1
20	Reply to the letter to the editor The harms of low-dose aspirin prophylaxis are overstated by P. Elwood and G. Morgan. <i>Annals of Oncology</i> , 2015 , 26, 442-3	10.3	1
19	Gene-signature-based prognostic tools in breast cancer: not yet. <i>Lancet, The</i> , 2007 , 369, 1428	40	1
18	Trastuzumab for early breast cancer. <i>Lancet, The</i> , 2006 , 367, 108	40	1
17	Medical research in India. <i>Lancet, The</i> , 2006 , 368, 643-4	40	1
16	Optimum cancer care--an unaffordable goal?. <i>Lancet Oncology, The</i> , 2004 , 5, 530	21.7	1

15	Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review. <i>The Cochrane Library</i> , 2018 ,	5.2	1
14	PSA testing for prostate cancer screening--authorsPreply. <i>Lancet Oncology, The</i> , 2015 , 16, e3	21.7	0
13	WITHDRAWAL-Administrative Duplicate Publication: The essential role of prevention in reducing the cancer burden in Europe: a commentary from Cancer Prevention Europe. <i>Tumori</i> , 2020 , 106, NP2-NP4	1.7	0
12	A major flaw in "Awareness of breast cancer and barriers to breast screening uptake in Bangladesh: A population based survey". <i>Maturitas</i> , 2016 , 88, 45	5	
11	Tackling breast cancer in India. <i>Lancet, The</i> , 2012 , 379, 2340-1	40	
10	Comment on "Dynamic response to heat--a novel physical characteristic of breast cancer". <i>International Journal of Surgery</i> , 2009 , 7, 173	7.5	
9	MRI breast screening. <i>Lancet, The</i> , 2008 , 371, 1415; author reply 1416	40	
8	Developing countries: an evolving opportunity for oncologic research. <i>World Journal of Surgery</i> , 2006 , 30, 1173-6	3.3	
7	Prognostic factors in invasive breast carcinoma: Do new molecular techniques/profiling add significantly to traditional histological factors?. <i>Current Diagnostic Pathology</i> , 2007 , 13, 116-125		
6	Does primary tumor location have prognostic significance in operable breast cancer?. <i>Nature Clinical Practice Oncology</i> , 2005 , 2, 396-7		
5	Radical and simple mastectomy. <i>New England Journal of Medicine</i> , 2002 , 347, 2170-1; author reply 2170-1	59.2	
4	Tuning into the genetic orchestra using microarrays: limitations of DNA microarrays in clinical practice. <i>Nature Clinical Practice Oncology</i> , 2006 , 3, E1-E1		
3	Aspirin and Cancer 2018 , 85-85		
2	Herceptin in early breast cancer: a call for judicious use. <i>The National Medical Journal of India</i> , 2005 , 18, 315-7	0.4	
1	Cancer immunotherapeutics: raising the ante. <i>The National Medical Journal of India</i> , 2006 , 19, 140-50	0.4	